文献速递肿瘤 PET/CT

11C-胆碱PET/CT在复发性前列腺癌中的应用:美国大型患者系列回顾性分析

11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series.
PubMed 文献 · J Nucl Med · 2019-12-20

该回顾性研究分析了287例疑似生化复发前列腺癌患者的11C-胆碱PET/CT,评估其检测性能并绘制复发模式。将评分1和2视为阳性时,66%的扫描为阳性;仅评分2时阳性率为54%。多因素分析仅PSA水平与扫描阳性显著相关,盆腔淋巴结是最常见复发部位,28%患者怀疑复发位于初始治疗野之外。

要点

  • 11C-胆碱PET/CT在PSA<0.5 ng/mL患者中阳性率45%(评分1+2)或28%(仅评分2)。
  • PSA≥2.0 ng/mL患者阳性率达90%(评分1+2)或81%(仅评分2)。
  • 盆腔淋巴结是最常见复发部位,28%患者怀疑复发在初始治疗野外。

核心结论

  • 11C-胆碱PET/CT结合临床背景可检测低PSA水平的前列腺癌复发。
  • 在前列腺特异性膜抗原显像剂完全获批前,胆碱PET/CT可能提供临床效用。

研究设计与样本

  • 回顾性分析287例因PSA升高(均值3.43 ng/mL,中位0.94 ng/mL,范围0.15-89.91 ng/mL)入组显像方案并怀疑复发的前列腺癌患者的11C-胆碱PET/CT。
  • 187例接受根治性前列腺切除术(其中79例接受辅助放疗),30例接受原发放疗,70例初始治疗后持续PSA升高(69例术后,1例放疗后)。
  • 由2名阅片者按0(阴性)、1(可疑)、2(阳性)评分,采用PROMISE标准绘制复发模式。

主要发现

  • 将评分1和2视为阳性时,2名阅片者共识判定66%的扫描为阳性。
  • 按PSA分层,评分1或2的阳性率:PSA<0.5 ng/mL为45%,0.5-0.99 ng/mL为56%,1.0-1.99 ng/mL为70%,≥2.0 ng/mL为90%。
  • 仅评分2时,总阳性率为54%;PSA<0.5、0.5-0.99、1.0-1.99、≥2.0 ng/mL组分别为28%、46%、62%、81%。
  • 多因素分析中仅PSA水平与扫描阳性显著相关。
  • 模式分析显示盆腔淋巴结是最常见复发部位,28%患者有11C-胆碱阳性的怀疑复发位于初始治疗野之外。

临床怎么用

  • 对于生化复发前列腺癌患者,11C-胆碱PET/CT可结合PSA水平等临床背景解读,低PSA时仍可能检出复发。
  • 在PSMA显像剂未完全获批的情况下,胆碱PET/CT可作为可选的显像手段。

局限性

  • 回顾性研究设计。
  • 来自单一非欧洲人群的大样本系列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to evaluate the performance of 11C-choline PET/CT in detecting biochemically recurrent prostate cancer (PCa) in a large non-European cohort (in the context of emerging evidence for prostate-specific membrane antigen PET in this setting) and to map patterns of PCa recurrence. Methods: We retrospectively analyzed 11C-choline PET/CT scans from 287 patients who were enrolled in an imaging protocol based on rising prostate-specific antigen (PSA) levels (mean, 3.43 ng/mL; median, 0.94 ng/mL; range, 0.15-89.91 ng/mL) and suspected recurrent PCa. A total of 187 patients had undergone primary radical prostatectomy (RP) (79/187 had secondary radiotherapy), 30 had undergone primary radiotherapy, and 70 had a persistent PSA elevation after receiving initial treatment (69 after RP, 1 after radiotherapy). The level of suspicion for recurrence on 11C-choline PET/CT was scored (0, negative; 1, equivocal; 2, positive) by 2 readers. The correlation between 11C-choline PET/CT positivity and initial treatment, Gleason score, National Comprehensive Cancer Network stage, PSA level, PSA doubling time, PSA velocity, and time between initial treatment and PET imaging was evaluated. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria were used to map 11C-choline recurrence patterns. Results: Considering scores 1 and 2 as positives, consensus between the 2 readers deemed 66% of the 11C-choline PET/CT scans as positive. When sorted by PSA level, 45% of patients with a PSA of less than 0.5 ng/mL, 56% of patients with a PSA of 0.5-0.99 ng/mL, 70% of patients with a PSA of 1.0-1.99 ng/mL, and 90% of patients with a PSA of at least 2.0 ng/mL scored either 1 or 2 on 11C-choline PET/CT scans. When considering scores of 2 only, 11C-choline PET/CT positivity was 54% (28%, 46%, 62%, and 81%, respectively, for patients with PSA < 0.5 ng/mL, 0.5-0.99 ng/mL, 1.0-1.99 ng/mL, and ≥ 2.0 ng/mL). In multivariate analysis, only PSA level was significantly associated with scan positivity. Pattern analysis showed that pelvic lymph nodes were the most common site of recurrence, and 28% of patients had 11C-choline-positive suspected recurrences outside the initial treatment field. Conclusion:11C-choline PET/CT can detect PCa recurrence even among patients with low PSA levels when interpretation accounts for the clinical context, providing a certain pretest probability. Until prostate-specific membrane antigen agents are fully approved for PCa, choline PET/CT may provide clinical utility.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Michaud L, Touijer KA, Mauguen A, et al. 11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series. J Nucl Med. 2019. PMID: 31862801. doi:10.2967/jnumed.119.233098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。